Source disclosure: February 04, 2026
KYORIN Pharmaceutical Co., Ltd. [4569.T]
TOKYO, Feb 04 (Pulse News Wire) – Kyorin Pharmaceutical CO.,LTD. (4569.T) announced today that it has received approval from the Ministry of Health, Labour and Welfare for its new influenza nucleic acid test kit, "GeneSoC FluA/B Detection Kit".
The company plans to launch sales of the product in the first half of fiscal year 2026. This kit, designed to assist in diagnosing influenza types A and B within approximately 15 minutes, uses the company's proprietary microfluidic technology based on real-time PCR methods. It offers improved detection sensitivity and shorter testing times compared to the existing "GeneSoC Influenza Virus A/B Detection Kit".
The new kit is expected to contribute significantly to rapid diagnosis of influenza, especially in early-stage patients. In addition to this latest development, KYORIN continues to advance the research and commercialization of other GeneSoC-based diagnostic products aimed at respiratory infections. The company remains committed to enhancing diagnostics, prevention, and treatment of infectious diseases through its innovative solutions.
The impact of this approval on the company’s earnings forecast for the fiscal year ending March 2026 is anticipated to be minor.
AI-translated content. 🟢 Confidence: High See terms • Original filing